Clinical Trial

A Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ZKLJ02 Injection in Healthy Chinese Research Participants

Study acronym: ZKLJ02-I
Completed Phase 1
View on ClinicalTrials.gov →
Summary
A randomized, double-blind, placebo-controlled, dose-escalation Phase I clinical study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of single intravenous administration of ZKLJ02 injection in healthy Chinese research participants
Trial Details
NCT Number NCT07638098
Lead Sponsor Yunnan Zhongke Longjin Biotechnology Co.,Ltd.
Conditions Evaluate the Safety and Tolerability of ZKLJ02 Injection in Healthy Chinese Research Participants
Enrollment 50 participants
Start Date 2025-08-11
Primary Completion 2025-11-18 (estimated)
Study Completion 2025-11-18 (estimated)
Updated on ClinicalTrials.gov 2026-06-10